Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2003 / Article

Original Article | Open Access

Volume 17 |Article ID 131943 | https://doi.org/10.1155/2003/131943

David N Moskovitz, Pooma Manoharan, E Jenny Heathcote, "High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C", Canadian Journal of Gastroenterology and Hepatology, vol. 17, Article ID 131943, 4 pages, 2003. https://doi.org/10.1155/2003/131943

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C

Abstract

OBJECTIVES: Approximately 60% of patients with chronic hepatitis C treated with a combination of interferon (IFN) alpha-2b and ribavirin are nonresponders. The purpose of the present study was to evaluate the efficacy of treatment with high dose consensus IFN (CIFN) (15 µg/day) in nonresponders.METHODS: Patients were administered 15 µg CIFN/day. Treatment was stopped in those whose serum hepatitis C virus (HCV) RNA remained detectable at 12 weeks. Those with undetectable HCV RNA at 12 weeks continued on 15 µg three times per week for a further 36 weeks.RESULTS: Twenty-four patients were recruited; six (25%) withdrew before 12 weeks because of side effects. Of the 18 patients who completed 12 weeks of therapy, nine (38%) had undetectable HCV RNA. Seven of nine patients who were HCV RNA-negative at week 12 completed 48 weeks of treatment and two withdrew because of intolerable side effects. At 48 weeks, HCV RNA remained undetectable in three patients. After six months of follow-up off treatment, two patients (8%) continued with no detectable HCV RNA in their sera.CONCLUSIONS: High dose induction therapy with CIFN 15 µg/day in prior nonresponders to IFN alpha-2b and ribavirin led to loss of detectable HCV RNA in 50% of patients, but this response was only sustained in 8% of patients on completion of therapy.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views54
Downloads231
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.